Generic Drugs

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Trump announces 100% tariff on imported generic drugs from August 2028

Trump has seized on the cost of drugs as a key driver of affordability concerns ahead of the 2026 midterm elections

Sun Pharma gets South Africa approval for generic semaglutide, launch soon

Sun Pharma has secured South Africa's approval for its generic semaglutide injection and plans to launch the once-weekly diabetes treatment in the coming days

Fat-loss drug sales in India loses steam after early spike from generics

The slowdown marks a sharp deceleration from the initial rush that followed the expiry of semaglutide's patent in March

Looking beyond generics: Wockhardt is showing the way in antibiotics

Wockhardt's FDA-approved Zaynich marks a breakthrough in India's pharmaceutical innovation, offering a new weapon against antimicrobial resistance

India extends lead over China in US FDA drug master filing in Q1FY26

Indian companies filed 184 Type II DMFs with the US FDA in Q1 2026 against China's 149, reinforcing the country's leadership in API manufacturing and future generic drug development

Alembic Pharma gets tentative approval from USFDA for generic cancer drug

Alembic Pharmaceuticals Ltd on Friday said it has received tentative approval from the US health regulator for its generic version of cancer treatment drug Binimetinib tablets. The tentative approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of Binimetinib tablets of strength 45 mg, Alembic Pharmaceuticals said in a regulatory filing. Based on USFDA's paragraph IV certifications list, Alembic is the sole first applicant to have filed its ANDA for Binimetinib Tablets, 45mg and upon final approval of this ANDA by the USFDA, the company may be eligible for 180 days of generic marketing exclusivity in the US, the company said. Alembic had previously received tentative approval for Binimetinib Tablets, 15mg, it added. Binimetinib in combination with encorafenib is used for the treatment of patients with unresectable or metastatic melanoma with resistance to specific targeted therapies in cancer. It is also indicated, in combination

Dr Reddy's launches generic oral leukaemia drug Bosutinib in US market

The company has launched a generic version of Pfizer's Bosulif for chronic myeloid leukaemia and secured 180 days of exclusivity for the 400 mg strength

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

How Chinese oral GLP-1 drugs may reshape India's obesity drug market

With cheaper GLP-1 pills entering India, access could improve significantly, but experts warn that affordability must be balanced with strong regulation and patient safety

Brazil rejects Dr Reddy's, Cipla GLP-1 generics on technical grounds

Brazil's regulator Anvisa rejects DRL and Cipla's generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

Eli Lilly's Mounjaro sales dip as semaglutide generics flood Indian market

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show

Centre increases monitoring of weight-loss drugs, flags safety concerns

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

Trump to impose up to 100% tariffs on imported drugs with some exemptions

Duties for products made by certain larger companies will take effect in 120 days, while items from smaller manufacturers won't be hit for another 180 days, according to a White House statement

Lupin gets tentative nod from USFDA for generic Sugammadex injection

Pharma major Lupin Ltd on Tuesday said it has received tentative approval from the US health regulator for its generic version of Sugammadex injection used for reversing the effects of muscle relaxants given during surgery. The tentative approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Sugammadex Injection of strengths 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial, Lupin said in a regulatory filing. The USFDA has tentatively approved Lupin's Sugammadex injection of the specified strengths as bioequivalent to Merck's Bridion injection, it added. It is used for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery, the company said.

Study finds new biomarker for cognitive symptoms of schizophrenia

A study has found a new biomarker of schizophrenia, which could also serve as a drug target for treating cognitive symptoms such as disorganised thinking or executive function. Schizophrenia is a mental health disorder marked by an impaired ability to perceive and interpret reality and can involve delusions and disorganised thinking, or cognitive symptoms. Researchers from the US' Northwestern University said that schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms. "A lot of people with schizophrenia cannot integrate well into society because of these cognitive deficits," author Peter Penzes, professor of neuroscience, pharmacology and psychiatry and behavioral sciences at Northwestern University's school of medicine, said. "Our discovery could solve these challenges by establishing the basis of a revolutionary and completely novel treatment strategy through a tandem biomarker-peptide therapeutic approach," Penzes ...

Semaglutide prices crash up to 90% as 15+ generics launch in two days

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Aurobindo arm launches Pomalidomide generic in US, adds to oncology line

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Glenmark to launch generic sodium phosphates injection in US in April 2026

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.